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CC BY-NC-ND license (http://creativeAbstract Two recent studies provide intriguing evidence that challenges the role of the
epithelialemesenchymal transition (EMT) as a critical mediator of cancer metastasis, while
revealing an unexpected role in cancer drug resistance.1,2 While these findings may not settle
the EMT’s role in metastasis, these studies suggest that targeting the EMT may inhibit both can-
cer metastasis and chemoresistance.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).The phenomenon whereby epithelial cells can lose their
epithelial characteristics and acquire mesenchymal char-
acteristics was first described in the early 1980s.3 This
dramatic cell transposition process, known as the epi-
thelialemesenchymal transition (EMT), not only plays crit-
ical roles in governing embryonic development and
maintaining adult tissue hemostasis (e.g., via regulating
wound healing and stem cell behavior), but also contributes
to many pathological conditions, such as fibrosis and cancer
progression.4e7 The EMT process is regulated by several key
transcription factors, such as SNAIL, zinc-finger E-box-
binding (ZEB) and basic helixeloopehelix transcription
factors, which are further controlled by multiple signaling
pathways, such as the TGFb and WNT pathways, in response
to extracellular cues.5e9
It is well accepted that the EMT plays an important role
in cancer metastasis. It has been considered that the non-
motile epithelial cancer cells at the primary site first ac-
quire the migratory characteristics of mesenchymal cellsity of Chongqing Medical
16.01.002
ng Medical University. Production
commons.org/licenses/by-nc-nd/and then undergo a reverse mesenchymal-to-epithelial
transition (MET) when they seed at a secondary site.5,8,10
The metastatic tumors formed at the secondary site
display the same epithelial cell phenotype as the cancer
cells at the primary site, leaving little evidence of their
transient mesenchymal state. This notion of an EMT-
induced early stage of metastasis has been supported by
numerous in vitro studies and mouse models of metastatic
human cancers, but the clinical evidence supporting the
occurrence of EMT in tumor specimens has been limited.
However, two recent studies presented data that high-
lighted an unexpected role of the EMT in cancer drug
resistance, while challenging the role of the EMT as a crit-
ical process for cancer metastasis.1,2
In one study, Fischer et al created two mouse models of
mammary tumors that develop spontaneous metastases,
which were traced by Cre-mediated switching of fluorescent
markers.1 The transgenic mice expressing either PyMT or the
Neu oncogene in the mammary gland harbored a Cre-
switchable fluorescent marker in the cells expressing
fibroblast-specific protein 1 (Fsp1; indicating early EMT)
which changed from red fluorescent protein (RFP) to greenand hosting by Elsevier B.V. This is an open access article under the
4.0/).
4 Commentaryfluorescent protein (GFP). Thus, GPF-positive cells were
indicative of the EMT, and persisted in the progeny of these
cells after they reverted to an epithelial fate because their
GFP expression was not reversible. They found that the
development of primary tumors and spontaneous lung me-
tastases in these tri-PyMT and tri-Neu mouse models was
indistinguishable from that in controls. However, the tumor
cells in the lung metastases were RFP-positive, indicating
that they had never undergone the EMT or expressed Fsp1.
Using the tri-PyMT mouse model that switched from RFP-
positive to GFP-positive when vimentin (Vim, another EMT
marker) was expressed, the authors found that the lung
metastases in the tri-PyMT/Vim mice were also RFP-positive.
Furthermore, the authors orthotopically injected tri-PyMT or
tri-PyMT/Vim tumor cells into wild-type mice and showed
that inhibiting the EMT by expressing miR-200, which targets
transcription factors required for the EMT (Zeb1 and Zeb2),
failed to inhibit metastasis following orthotopic injection.
Surprisingly, while the treatment of mice bearing orthotopic
tri-PyMT tumors with cyclophosphamide reduced primary
tumor size, many metastatic tumors in the treated mice
contained a significant number of GFP-positive cells, which
expressed many factors implicated in proliferation and the
resistance to chemotherapy, suggesting that these metasta-
tic cells may become more resistant to cyclophosphamide in
an EMT-dependent manner.
In a companion study, Zheng et al reported similar
findings using tissue-specific deletion of the EMT-inducing
transcription factors Snail or Twist to assess the conse-
quences of the EMT in a mouse model of pancreatic ductal
adenocarcinoma (PDAC), in which mice develop metasta-
tic tumors due to the expression of mutant p53 and KRAS-
G12D in pancreatic cells.2 When these mice were crossed
with mice lacking the EMT transcription factor Snail1 or
Twist1, there were similar numbers of metastases in the
liver, lungs and spleen in these EMT-deficient mice and the
EMT-competent mice. Moreover, the authors showed that
suppressing the EMT had no effect on the number of
circulating tumor cells, the ability of tumor cells to form
tumor spheres or colonize the lung following intravenous
injection, or the overall frequency of metastasis. Howev-
er, suppressing the EMT in these PDAC mice reduced the
tumor progression and increased the survival of mice when
they were treated with gemcitabine. Using another PDAC
model which expressed mutant KRAS and lacked TGF-b
receptor 2 (TGFbR2), the authors also found that knocking
out Snai1 did not prevent the development of metastatic
PDAC, while it enhanced the sensitivity of their tumors to
gemcitabine, suggesting a role for the EMT in cancer drug
resistance.
Both of these reports provide convincing evidence link-
ing the EMT to cancer drug resistance, which may be caused
by an enhancement of cancer cell survival, cell fate tran-
sition, and/or up-regulation of drug resistance-related
genes. At the same time, both studies challenge the cur-
rent prevailing view of the EMT’s role in cancer metastasis.
However, the EMT is a highly complex cellular process that
is regulated by multiple signaling molecules and transcrip-
tion factors. In fact, the precise mechanism(s) underlying
the EMT are still not fully understood. Thus, the possiblelimitations of the tumor models used by Fischer et al and
Zheng et al need to be considered before EMT’s role in
cancer metastasis and tumor invasion can be dismissed
outright.
First, tracing the EMT switch phenotype on the basis of
the expression of a single gene may not fully represent the
complicated nature of the process. Second, an effective
suppression of the EMT may not be accomplished by simply
inactivating either Snail or Twist, because both are known
to function redundantly in many contexts. Third, the acute
nature of the transgenic tumor models used in these studies
may over-exaggerate the tumorigenic and metastatic pro-
cesses that occur in the clinical setting, as the EMT may
provide a metastatic advantage to slower-growing tumors.
Fourth, the transgenic tumors used in these studies may
have lacked intra-tumoral heterogeneity because they
were driven by the expression of a few cancer-initiating
genes, which may further affect the impact of the EMT on
the tumors’ invasiveness and metastatic potential. Fifth,
without fully understanding the molecular mechanisms
governing the EMT, it may not be possible to recapitulate
the full process of the EMT that may occur spontaneously in
cancer cells using highly simplified mouse tumor models.
Lastly, it is worth noting that cancer metastasis and cancer
drug resistance are two complex and poorly understood
processes, which often co-exist clinically. Thus, there are
tremendous challenges ahead to overcome these hurdles in
order to achieve effective cancer treatment. Nonetheless,
the good news coming from these studies is that targeting
the EMT may be able to “kill two birds with one stone”,
providing a better therapeutic outcome.
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